炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 责任编辑：宋雅芳 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 近日，中邮证券发布研究报告，维持对"AI+医疗"行业"强于大市"的评级，认为该行业在政策与产业共 振下正迎来加速发展。华大智造、华大基因、晶泰控股、英矽智能、联影智能、鹰瞳科技等多家行业内 企业获关注。 近日，中邮证券发布研究报告，维持对"AI+医疗"行业"强于大市"的评级，认为该行业在政策与产业共 振下正迎来加速发展。华大智造、华大基因、晶泰控股、英矽智能、联影智能、鹰瞳科技等多家行业内 企业获关注。 研报指出，全球AI医疗市场预计将从2022年的137亿美元迅猛增长至2030年的1553亿美元。政策层面， 国家多部门联合推动"人工智能+制造"，重点鼓励AI在高端医疗装备等场景的应用，为行业注入强心 剂。同时，海外领先企业如TempusAI业绩高增、英伟达与礼来巨额投资共建AI实验室等动向，也强化 了全球产业高景气度的预期。 报告分析，AI技术已在制药、辅助诊断、影像手术及医疗服务等多个医疗细分领域步入成熟。在辅助 诊断方向，具备高质量数据与技 ...

Core Insights - The 44th J.P. Morgan Healthcare Conference has highlighted significant industry developments, including a $1 billion investment by NVIDIA and Eli Lilly to establish a joint research lab in the San Francisco Bay Area to accelerate AI applications in the pharmaceutical sector [1] - The conference serves as a critical platform for domestic pharmaceutical companies to showcase core molecular product capabilities and advance overseas business development collaborations, indicating a return to global value validation for products [2] - The participation of over 8,000 global attendees and more than 500 listed companies underscores the strengthening global competitiveness of Chinese companies in the pharmaceutical sector [2] Group 1: Innovative Drugs - BeiGene focuses on oncology drug development and global commercialization, presenting progress on core products like CDK4 at the conference [2] - Rongchang Biologics has entered an exclusive licensing agreement with AbbVie for the novel PD-1/VEGF bispecific antibody drug RC148, granting AbbVie rights outside Greater China for development, production, and commercialization [2] - Hengrui Medicine, involved in the R&D, production, and sales of innovative and generic drugs, reported that over 50% of its revenue now comes from innovative drugs, with multiple self-developed products receiving approvals [2] Group 2: CRO/CMO - WuXi AppTec provides integrated CXO services covering the entire drug development and manufacturing process, projecting a 32.56% year-on-year growth in net profit for 2025 [3] - WuXi Biologics, specializing in biopharmaceutical CRDMO services, announced 209 new projects, bringing the total to 945, with potential milestone payments exceeding $4 billion from new research contracts [3] - Tigermed offers clinical trial CRO services and participated in the Asia-Pacific session of the conference, providing outsourcing services related to clinical trials for global pharmaceutical companies [3] Group 3: AI in Healthcare - NVIDIA and Eli Lilly's collaboration aims to build AI models to enhance new drug development, with a planned investment of $1 billion over the next five years [4] - RunDa Medical focuses on comprehensive medical testing services and is developing an automated testing interpretation system based on large models [4] - Anbiping has launched a digital pathology AI system and is exploring the registration and commercialization of AI medical devices in cervical cytology [4]

Q&A 润达医疗在 2025 年的整体经营情况如何？传统主业和 AI 业务的发展现状是 什么？ 润达医疗 20260114 摘要 润达医疗预计 2026 年传统主业经营反转，AI 业务进展顺利，已与约 160 家大型三甲医院落地合作，并与华为、华鲲振宇合作推出轻量化一 体机智能体，已商业化 15 套。 公司与华为、华鲲振宇合作推出的轻量化一体机智能体已签约约 180 套， 另有 300 多套意向订单，计划半年内推广至全国数百上千家医院，加速 AI 产品临床应用。 润达医疗近期在拉丁美洲和中东签订合同，AI 医疗产品成功进入海外市 场，产品在性能和成本方面均具优势。 公司通过 To B To C 模式布局 C 端市场，与华西医院、天津泰心医院、 中国抗癌协会等合作，针对慢病患者、高频就医人群开发 C 端产品，提 升品牌力。 医院对 AI 服务器及大模型 Agent 的需求集中在临床提质增效、科研创 新和患者就医服务体验提升三个方向，不同科室可能需要单独配置 AI 设 备。 医院对 AI 医疗产品的需求主要集中在诊前预问诊导诊、诊后患者教育管 理和健康管理等方面，基层医院、社区医院需求更为迫切。 公司通过与华西、 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603108 证券简称：润达医疗 公告编号：临2026-009 转债代码：113588 转债简称：润达转债 上海润达医疗科技股份有限公司关于持股5%以上 股东权益变动触及5%刻度的提示性公告 股东朱文怡及刘辉保证向本公司提供的信息真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： ■ 一、信息披露义务人及其一致行动人的基本信息 ■ 2.信息披露义务人信息 ■ 3、一致行动人信息 1.身份类别 ■ 二、权益变动触及5%刻度整数倍的基本情况 上海润达医疗科技股份有限公司（以下简称"公司"）于2026年1月14日收到股东朱文怡和刘辉发来的 《简式权益变动报告书》，获悉其通过集中竞价方式减持公司股票合计2,678,999股，占公司股份总数的 0.44%；另因公司可转债转股被动稀释0.12%，合计持有公司股份比例由10.56%变动为10.00%，触及5% 刻度的整数倍。具体情况如下： ■ 公司可转债处于转股期，本公告以在中国证券登记结算有限责任公司查询的2026年1月13 ...

上海润达医疗科技股份有限公司 简式权益变动报告书 上市公司名称：上海润达医疗科技股份有限公司 股票上市地点：上海证券交易所 股票简称： 润达医疗 股票代码： 603108 信息披露义务人一：朱文怡 住所及通讯地址：上海市虹口区**** 信息披露义务人二：刘辉 住所及通讯地址：上海市虹口区**** 权益变动性质：股份减少、股份比例被动稀释 签署日期：二零二六年一月十四日 1 信息披露义务人声明 一、本报告书系依据《中华人民共和国公司法》、《中华人民共和国证券法》、 《上市公司收购管理办法》、《公开发行证券的公司信息披露内容与格式准则第 15 号——权益变动报告书》及相关的法律、法规和规范性文件编写； 二、信息披露义务人签署本报告书已获得必要的授权和批准； 三、依据《中华人民共和国证券法》、《上市公司收购管理办法》的规定，本 报告书已全面披露了信息披露义务人在上海润达医疗科技股份有限公司（以下简 称"润达医疗"或"公司"）中拥有权益的股份变动情况； 四、截至本报告书签署之日，除本报告书披露的信息外，上述信息披露义务 人没有通过任何其他方式增加或减少其在润达医疗拥有权益的股份； 五、本次权益变动是根据本报告所载明的 ...

| 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 2026-009 | | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | 上海润达医疗科技股份有限公司 关于持股 5%以上股东权益变动触及 5%刻度的提示性公告 股东朱文怡及刘辉保证向本公司提供的信息真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一 致。 重要内容提示： | 权益变动方向 | 比例增加□ | | 比例减少 | | --- | --- | --- | --- | | 权益变动前合计比例 | 10.56% | | | | 权益变动后合计比例 | 10.00% | | | | 本次变动是否违反已作出的承 诺、意向、计划 | 是□ | 否 | | | 是否触发强制要约收购义务 | 是□ | 否 | | 一、 信息披露义务人及其一致行动人的基本信息 1.身份类别 | | □控股股东/实际控制人及其一致行动人 | | --- | --- | | 投资者及其一致 | 其他 5%以上大股东及其一致行动人 | | | ...

格隆汇1月14日丨润达医疗(603108.SH)公布，上海润达医疗科技股份有限公司于2026年1月14日收到股 东朱文怡和刘辉发来的《简式权益变动报告书》，获悉其通过集中竞价方式减持公司股票合计267.90万 股，占公司股份总数的0.44%；另因公司可转债转股被动稀释0.12%，合计持有公司股份比例由10.56% 变动为10.00%，触及5%刻度的整数倍。 ...

格隆汇1月14日丨润达医疗(603108.SH)公布，上海润达医疗科技股份有限公司于2026年1月14日收到股 东朱文怡和刘辉发来的《简式权益变动报告书》，获悉其通过集中竞价方式减持公司股票合计267.90万 股，占公司股份总数的0.44%；另因公司可转债转股被动稀释0.12%，合计持有公司股份比例由10.56% 变动为10.00%，触及5%刻度的整数倍。 ...

润达医疗公告称，股东朱文怡和刘辉于2024年2月9日至2026年1月14日，通过集中竞价减持公司股票 267.8999万股，占公司股份总数的0.44%，另因可转债转股被动稀释0.12%。二者合计持股比例由10.56% 降至10.00%，触及5%刻度整数倍。此次权益变动不会导致公司控股股东及实际控制人发生变化。 ...

Group 1: AI in Healthcare - Morgan Stanley's healthcare conference highlighted a partnership between Nvidia and Eli Lilly, investing $1 billion over five years to establish a joint research lab in the San Francisco Bay Area to accelerate AI drug development [1] - OpenAI launched ChatGPT Health, allowing users to securely connect medical records and health applications to an AI chatbot for health consultations and data interpretation [1] - Ant Group's AI health assistant "Ant Aifu" gained significant user attention by linking multiple hospitals and real doctors for health consultations and medical services [1] Group 2: Market Trends and Insights - CITIC Securities reported that by 2026, AI healthcare payment sources will become clearer and more robust, enhancing the commercial viability of AI in healthcare and accelerating the restructuring of the pharmaceutical market [2] - Aijian Securities noted rapid development in AI healthcare across policy, technology, products, and application scenarios, with future applications expected to extend from tertiary hospitals to grassroots terminals and individual users [2] - Guojin Securities emphasized that the Morgan Stanley healthcare summit serves as a global investment barometer, with several Chinese companies planning presentations that could boost expectations for innovative drug business development [2] Group 3: AI Medical Companies - Runta Medical launched a large model-based interpretation system for complex report analysis, assisting doctors in decision-making, and is developing automated pre-processing robots and logistics AGVs for sample handling [2] - Anbiping focuses on pathology diagnosis with digital pathology AI that can automatically identify cancerous areas and generate structured reports, while also developing automated slide scanning and staining robots [3] - United Imaging leverages AI in high-end medical imaging equipment, with an AI-assisted diagnostic system that can mark lesions in CT and MRI scans in real-time [3] Group 4: AI Drug Development - Hongbo Pharmaceutical has developed an AI drug design platform that supports new drug projects through CADD/AIDD technologies [4] - Chengdu XianDao is building a closed-loop R&D platform integrating a trillion-level small molecule compound library with AI and automation [4] - Hanyu Pharmaceutical collaborates with Huawei to develop a large model for peptide and oligonucleotide drug research, utilizing AI for molecular design and virtual screening [4] Group 5: CRO/CMO Services - WuXi AppTec operates as a fully integrated biopharmaceutical service platform, covering chemical drugs and cell gene therapies with global operational presence [5] - Zhaoyan New Drug focuses on preclinical CRO services, emphasizing safety evaluations and participating in clinical evaluations for stem cell and CAR-T cell therapies [5] - Tigermed provides full-process clinical trial services, with its subsidiary developing an AI model platform for new drug research and clinical trial support [6]